Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOncolytics Biotech Inc

Oncolytics Biotech Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.3818 USD -0.03 ( 6.35%)
Last update at 2026-11-10T21:00:00Z
VOLUME
538371
Market Cap
82.96M

Momentum Score

…

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.38
Low
0.42
High
52 Week Price Range
0.88
Low
3.39
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Oncolytics Biotech is a clinical-stage biotech developing an oncolytic virus intended to stimulate anti-tumor immunity and augment checkpoint inhibitors. Long-term growth drivers include positive clinical trial readouts, demonstration of benefit in combination regimens and potential strategic partnerships to support development. Investors may find the company attractive because its differentiated biologic approach could complement existing immunotherapies and create near- to mid-term data catalysts.

The principal investment risks are high clinical and regulatory failure risk, ongoing funding needs that could cause dilution, manufacturing and scalability challenges, and intense competition in oncology therapeutics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.41
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-115.80%
Net Debt
-31.11M
ROCE
-82.61%
Diluted EPS TTM
-0.29

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -24.75M -26.25M -22.51M -33.12M -16.49M
Minority interest - - - - 0.00M
Net income -24.84M -26.30M -19.55M -45.55M -17.04M
Selling general administrative 11.49M - - 9.56M 7.24M
Gross profit - - - - 0.00M
Reconciled depreciation 0.39M 0.45M 0.45M 0.49M 0.10M
Ebit -28.57M -26.23M -25.46M -20.69M -16.66M
Ebitda -28.18M -25.66M -27.85M -7.60M -16.57M
Depreciation and amortization 0.39M 0.57M -2.39M 13.09M 0.10M
Non operating income net other - - - - 0.00M
Operating income -28.57M -26.23M -25.46M -20.69M -16.66M
Other operating expenses 26.92M 26.23M 25.46M 20.69M 16.66M
Interest expense 0.53M 0.14M 0.00M 0.00M 0.00M
Tax provision 0.08M 0.05M 0.00M 0.00M 0.55M
Interest income 0.53M 0.10M 0.12M 0.18M 0.17M
Net interest income 0.53M 0.10M 0.12M 0.18M 0.17M
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense 0.08M 0.05M -2.95M 12.43M 0.55M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 26.92M 26.23M 25.46M 20.69M 16.66M
Cost of revenue - - - - 0.00M
Total other income expense net 3.82M -0.02M 2.95M -12.43M 0.17M
Discontinued operations - - - - 0.00M
Net income from continuing ops -24.84M -26.30M -22.51M -33.12M -17.04M
Net income applicable to common shares -24.84M -26.30M -22.51M -33.12M -17.04M
Preferred stock and other adjustments - - - - 0.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 38.82M 37.33M 45.88M 34.35M 19.66M
Other current assets 3.25M 3.02M 2.78M 2.43M 2.71M
Total liab 11.26M 10.83M 9.78M 9.59M 19.77M
Total stockholder equity 27.56M 26.50M 36.10M 24.75M -0.11M
Other current liab 4.10M 1.48M 2.40M 2.46M 12.53M
Common stock 430.91M 404.04M 391.35M 356.82M 311.08M
Capital stock 430.91M 404.04M 391.35M 356.82M 311.08M
Retained earnings -446.00M -418.25M -393.42M -367.11M -344.61M
Other liab - 6.73M 6.73M 6.73M 6.73M
Other assets 0.00M 1.00M - - -
Cash 31.53M 11.67M 41.26M 31.22M 14.15M
Total current liabilities 4.24M 3.94M 2.69M 2.71M 12.87M
Current deferred revenue -1.08M - - - -
Net debt -31.11M -11.29M -40.61M -30.82M -13.64M
Short term debt 0.13M 0.22M 0.29M 0.25M 0.34M
Short long term debt total 0.42M 0.37M 0.65M 0.40M 0.51M
Other stockholder equity 42.12M 40.05M 37.78M 34.64M 32.96M
Property plant equipment - 0.65M 0.98M 0.61M 0.73M
Total current assets 38.17M 35.68M 44.90M 33.74M 18.93M
Net tangible assets - 26.50M 36.10M 24.75M -0.11M
Short term investments 3.38M 20.47M - - -
Net receivables 0.01M 0.52M 0.87M 0.09M 2.07M
Accounts payable 1.08M 2.25M 1.99M 1.81M 3.17M
Accumulated other comprehensive income 0.54M 0.66M 0.39M 0.40M 0.46M
Common stock total equity - - - 356.82M 311.08M
Non currrent assets other -0.00M 1.00M - - 0.73M
Non current assets total 0.65M 1.65M 0.98M 0.61M 0.73M
Capital lease obligations 0.42M 0.37M 0.65M 0.40M 0.51M
Long term debt total - - - - 0.17M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -20.40M -0.29M -0.03M -0.01M -0.11M
Change to liabilities 1.66M 0.18M -1.37M 1.35M -1.31M
Total cashflows from investing activities -20.40M -0.29M -0.03M -0.01M -0.11M
Net borrowings -0.38M -0.37M -0.46M -0.45M -0.45M
Total cash from financing activities 12.21M 33.02M 39.77M 21.02M 13.30M
Change to operating activities -1.62M -0.31M -0.40M -1.13M 0.46M
Net income -24.84M -26.30M -22.51M -33.12M -17.04M
Change in cash -29.60M 10.04M 17.07M 0.45M 1.86M
Begin period cash flow 41.26M 31.22M 14.15M 13.70M 11.84M
End period cash flow 11.67M 41.26M 31.22M 14.15M 13.70M
Total cash from operating activities -23.36M -22.43M -22.07M -19.91M -11.92M
Issuance of capital stock 12.57M 32.91M 38.30M 18.00M 13.17M
Depreciation 0.39M 0.45M 0.45M 0.49M 0.10M
Other cashflows from investing activities - - - - 0.00M
Dividends paid - - - - 0.00M
Change to inventory - - - - 0.00M
Change to account receivables 0.34M -0.78M 1.98M -2.02M 4.77M
Sale purchase of stock - - - 13.33M 12.85M
Other cashflows from financing activities 0.01M 0.47M 1.94M 3.47M 0.12M
Change to netincome 0.70M 4.33M -0.22M 14.53M 1.12M
Capital expenditures 0.06M 0.29M 0.03M 0.01M 0.11M
Change receivables - - - - 0.00M
Cash flows other operating - - - - 0.00M
Exchange rate changes - - - - 0.00M
Cash and cash equivalents changes - - - - 0.00M
Change in working capital 0.39M -0.91M 0.21M -1.80M 3.90M
Stock based compensation 2.38M 3.83M 2.56M 1.47M 1.42M
Other non cash items -1.68M 0.09M 0.07M 0.09M 0.08M
Free cash flow -23.41M -22.72M -22.10M -19.92M -12.03M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ONCY
Oncolytics Biotech Inc		 -0.03
6.35%		 0.38 - - - 4.27 -1.79
NVO
Novo Nordisk A/S		 -0.68
1.64%		 40.70 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.02
0.55%		 547.85 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -
-%		 916.06 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Oncolytics Biotech Inc

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5

403 670 7377

https://www.oncolyticsbiotech.com

Name Title Year Born
Dr. Matthew C. Coffey M.B.A., Ph.D. Pres, CEO & Director NA
Mr. Kirk J. Look C.A., CA Chief Financial Officer NA
Mr. Andrew R. de Guttadauro Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc 1967
Dr. Thomas C. Heineman M.D., Ph.D. Chief Medical Officer NA
Ms. Allison Hagerman P.Eng., P.M.P. VP of Product Devel. NA
Jon Patton Director of Investor Relations & Communication NA
Dr. Grey Wilkinson Ph.D. Scientist of Translational Medicine NA
Mr. John Mark Lievonen F.C.A., FCA Consultant NA
Dr. Daniel Douglas Von Hoff F.A.C.P., FACP, M.D. Consultant 1948
Dr. Matthew C. Coffey M.B.A., Ph.D. President, CEO & Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…